Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment

被引：0
|
作者：
Yamin Shu
Lei Wang
Yiling Ding
Qilin Zhang
机构：
[1] Huazhong University of Science and Technology,Department of Pharmacy, Tongji Hospital, Tongji Medical College
[2] Chongqing University Central Hospital,Pharmacy Department, Chongqing Emergency Medical Center
[3] University of Tokyo,Graduate School of Pharmaceutical Sciences
[4] Huazhong University of Science and Technology,Department of Pharmacy, Union Hospital, Tongji Medical College
来源：
Drug Safety | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：881 / 895
页数：14
相关论文
共 50 条
  • [31] A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil
    Wang, Yan
    Zhao, Bin
    Yang, Haiyan
    Wan, Zheng
    [J]. ANDROLOGY, 2024, 12 (04) : 785 - 792
  • [32] A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
    Qi, Yiming
    Li, Jing
    Lin, Sisi
    Wu, Shuangshuang
    Chai, Kequn
    Jiang, Xin
    Qian, Jiancheng
    Jiang, Cheng
    [J]. SCIENTIFIC REPORTS, 2024, 14 (01):
  • [33] A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam
    He, Weizhen
    Wang, Yang
    Chen, Kaiqin
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [34] A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten
    Yukselen, Zeynep
    Raju, Arvind Kumar Venkataramana
    Kumar, Pramukh Arun
    Ujjawal, Aditi
    Dasari, Mahati
    Parajuli, Shreyash
    Nakhla, Michael
    Bansal, Kannu
    Ganatra, Sarju
    Dani, Sourbha S.
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2024,
  • [35] A real-world pharmacovigilance study of FDA adverse event reporting system events for atogepant
    Wen, Heli
    Ding, Yitian
    Chen, Feichi
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [36] A real-world pharmacovigilance study of FDA adverse event reporting system events for daratumumab
    Yun, Xiaolin
    Zhou, Yingying
    Wu, Danna
    Liu, Yuanbo
    Wu, Qiongshi
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (05) : 581 - 591
  • [37] A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System Events for Trametinib
    Zhang, Xinyue
    Li, Rongrong
    Li, Yanrong
    He, Lu
    Hou, Encun
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (08)
  • [38] Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
    Zhao, Dan
    Zhang, Wangxin
    Liu, Yan
    Yan, Zhaojun
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [39] The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system
    Wei, Wei
    Huang, Liang
    Bai, Yingtao
    Chang, En
    Liu, Jinfeng
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [40] A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System
    Shu, Yamin
    He, Xucheng
    Liu, Yanxin
    Wu, Pan
    Zhang, Qilin
    [J]. CLINICAL EPIDEMIOLOGY, 2022, 14 : 789 - 802
12345